Dr. Denk is the Chief Operating Office of Breath Therapeutics, a Zambon company. He has over 15 years of industry expertise in pharmaceutical operations and regulatory affairs.
Before co-founding Breath Therapeutics, Dr. Denk was the Vice President of the Business Unit Pharma at PARI Pharma, Germany, where he led the marketing authorization approvals of two inhaled antibiotics, ColiFin® and Vantobra®, for the treatment of cystic fibrosis, as well as facilitated, with his business unit, the approval of KITABIS™ in the US. Prior, he held the position of Director of Regulatory Affairs at PARI Pharma. Earlier in his career, Dr. Denk was the Quality Control Manager at Scil Biomedicals, a biotech company founded by former Boehringer Mannheim executives.
Dr. Denk earned his Master of Science degree with distinction in Pharmaceutical Sciences and a Ph.D. in Pharmaceutical Sciences from the University of Strathclyde, Glasgow, UK.